Caleb Roberts1,2, Claire L. Mitchell3,
James P. O'Connor, 23, Yvonne Watson1,2, Sue Cheung1,2,
Alison Backen4, Caroline Dive4, Alan Jackson1,2,
Gordon C. Jayson3, Geoff J. Parker1,2
1Imaging Science and Biomedical
Engineering, School of Cancer and Imaging Sciences, The University of
Manchester, Manchester, United Kingdom; 2The University of
Manchester Biomedical Imaging Institute, The University of Manchester, Manchester,
United Kingdom; 3Cancer Research UK Dept Medical Oncology,
Christie Hospital and University of Manchester, Manchester, United Kingdom; 4Clinical
and Experimental Pharmacology Group, Paterson Institute for Cancer Research,
Manchester, United Kingdom
The
integration of imaging strategies such as dynamic contrast-enhanced MRI
(DCE-MRI) in early phase drug development can help elucidate the underlying
tumor physiology and assess drug efficacy. This study focuses on the
relationships between serological expression of soluble VEGF receptors and
DCE-MRI tracer kinetic parameters in a group of ovarian tumors. We observe striking relationships between
the serological markers, Ktrans
and vp that indicate
that DCE-MRI is sensitive to specific aspects of the angiogenic process in
these tumors.